FindTrial
Sign In

NA - TRANSADO

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2019-000300-16-FR
Enrollment
60
Registered
2020-08-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NA MedDRA version: 20.0 Level: PT Classification code 10078075 Term: Gender dysphoria System Organ Class: 10037175 - Psychiatric disorders

Interventions

Trade Name: ANDROTARDYL 250 mg/1mL, solution injectable intramusculaire Product Name: ANDROTARDYL Pharmaceutical Form: Solution for injection INN or Proposed INN: TESTOSTERONE ENANTATE CAS Number: 315

Sponsors

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: NA Are the trial subjects under 18? yes Number of subjects for this age range: 60 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Main Objective: NA;Secondary Objective: NA;Primary end point(s): NA;Timepoint(s) of evaluation of this end point: NA—

Secondary

MeasureTime frame
Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA—

Countries

France

Contacts

Public ContactChef de projet

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

yannick.vacher@aphp.fr33144.84.17.30

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026